Literature DB >> 17243489

Drug evaluation: the C5a receptor antagonist PMX-53.

Jörg Köhl1.   

Abstract

Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17243489

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  37 in total

Review 1.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

3.  Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.

Authors:  Maria I Fonseca; Rahasson R Ager; Shu-Hui Chu; Ozkan Yazan; Sam D Sanderson; Frank M LaFerla; Stephen M Taylor; Trent M Woodruff; Andrea J Tenner
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 4.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

5.  PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells.

Authors:  Hariharan Subramanian; Sakeen W Kashem; Sarah J Collington; Hongchang Qu; John D Lambris; Hydar Ali
Journal:  Mol Pharmacol       Date:  2011-03-11       Impact factor: 4.436

6.  Improving the Fmoc Solid Phase Synthesis of the Cyclic Hexapeptide Complement C5a Antagonist, PMX205.

Authors:  R C Delisle Milton; S C Milton; A R Chamberlin
Journal:  Int J Pept Res Ther       Date:  2011-12       Impact factor: 1.931

7.  C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells.

Authors:  Donald J Weaver; Edimara S Reis; Manoj K Pandey; Gabriele Köhl; Nathaniel Harris; Craig Gerard; Jörg Köhl
Journal:  Eur J Immunol       Date:  2010-03       Impact factor: 5.532

Review 8.  Complement components as potential therapeutic targets for asthma treatment.

Authors:  Mohammad Afzal Khan; Mark R Nicolls; Besiki Surguladze; Ismail Saadoun
Journal:  Respir Med       Date:  2014-01-15       Impact factor: 3.415

9.  A recombinant vaccine effectively induces c5a-specific neutralizing antibodies and prevents arthritis.

Authors:  Kutty Selva Nandakumar; Asa Jansson; Bingze Xu; Niclas Rydell; Parvin Ahooghalandari; Lars Hellman; Anna M Blom; Rikard Holmdahl
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

Review 10.  Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis.

Authors:  Robert A DeAngelis; Edimara S Reis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.